Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Pyronaridine, a Mannich base synthetic antimalarial, was developed and commercialized in China but is not available elsewhere. Currently, the drug is not widely used because of its high cost and failure to meet international standards. However, despite common chemical features, it has proved effective in chloroquine-resistant falciparum malaria and would represent a valid addition to the armamentarium of antimalarial drugs, since it has potential for replacing chloroquine and for use in treating drug-resistant falciparum malaria. Nonetheless, there is at present no commercial partner interested in the drug, and there has been little progress towards an improved formulation, reduced cost-of-goods or international registration. Pyronaridine should be protected against resistance by combining it with a fast-acting antimalarial, namely an artemisinin derivative.


Journal article


Current Opinion in Anti-infective Investigational Drugs

Publication Date





71 - 75